Pelargonidin-Strontium Oxide Nanoparticles: Enhanced Targeted Therapy for Triple-Negative Breast Cancer
Journal of Biomedicine and Biosensors · 2026
DOI: 10.58613/jbb632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedicine and Biosensors, 2026. Verfasst von Peng Zhang und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a highly aggressive neoplasm characterized by restricted therapeutic alternatives and a bleak prognosis. Nanotechnology-driven medication delivery methods improve therapeutic effectiveness while minimizing systemic toxicity. Pelargonidin (PL), a flavonoid with anticancer effects, has low absorption, hence limiting its therapeutic applicability. Strontium oxide (SrO) nanoparticles provide a viable platform for medication administration owing to their biocompatibility. This work included the synthesis of PL-SrO nanoparticles using co-precipitation, followed by characterization utilizing FTIR, XRD and TEM techniques. Drug release investigations demonstrated a pH-dependent release profile, with 85% of PL released at pH 6.5 (conditions simulating tumors) in contrast to 60% at pH 7.4 during a 24-hour period. in vitro tests shown that PL-SrO markedly decreased TNBC cell viability (IC50 = 2.8 μg/mL) in comparison to free PL (IC50 = 7.2 μg/mL), while showing no damage to normal cells. PL-SrO demonstrated superior inhibition of colony formation (90% decrease), migration (85% reduction), and invasion (90% reduction) compared to free PL. Apoptotic staining and mitochondrial membrane potential studies validated substantial activation of apoptosis. The formation of ROS increased by 350% with PL-SrO therapy, exceeding the impact of doxorubicin (DOX). Gene expression study demonstrated a 3.0-fold overexpression of BAX and a 2.8-fold rise in Caspase 9, accompanied by a 0.3-fold downregulation of BCL2 and BRCA1, indicating the activation of apoptosis and the suppression of DNA repair. The results indicate that PL-SrO nanoparticles improve PL bioavailability, specifically target TNBC cells, and trigger death via mitochondrial malfunction and oxidative stress, therefore underscoring their potential as a nanotherapeutic for TNBC.
Zitieren
APA
Zhang, P., Wang, C., Qi, M., Hu, Q., Liu, W., & Zhang, Y. (2026). Pelargonidin-Strontium Oxide Nanoparticles: Enhanced Targeted Therapy for Triple-Negative Breast Cancer. Journal of Biomedicine and Biosensors. https://doi.org/10.58613/jbb632
Vancouver
Zhang P, Wang C, Qi M, Hu Q, Liu W, Zhang Y. Pelargonidin-Strontium Oxide Nanoparticles: Enhanced Targeted Therapy for Triple-Negative Breast Cancer. Journal of Biomedicine and Biosensors. 2026. doi:10.58613/jbb632
BibTeX
@article{Zhang2026,
author = {Zhang, Peng and Wang, Chao and Qi, Mengmeng and Hu, Qian and Liu, Wenwen and Zhang, Ying},
title = {Pelargonidin-Strontium Oxide Nanoparticles: Enhanced Targeted Therapy for Triple-Negative Breast Cancer},
journal = {Journal of Biomedicine and Biosensors},
year = {2026},
doi = {10.58613/jbb632}
}
EUVIMED